---

DM Thesis Framework: Febrile Neutropenia in Hematological Malignancies

---

1. Suggested Thesis Title Options

1. "Clinical Profile, Microbiological Spectrum, and Outcomes of Febrile Neutropenia in Patients with Hematological Malignancies: A Prospective Study from a Tertiary Care Center in Nepal"
2. "Bacteriological Profile and Antimicrobial Sensitivity Patterns in Febrile Neutropenia among Hematological Malignancy Patients at Civil Service Hospital, Kathmandu"
3. "Role of Buffy Coat Examination and Blood Culture in the Diagnostic Workup of Febrile Neutropenia in Hematological Malignancies" (if the buffy coat angle is the primary focus)

Tip: For a DM thesis in Nepal, option 1 or 2 is more feasible and publishable. The buffy coat can be incorporated as one of the diagnostic tools evaluated.

---

2. Rationale / Gap in Literature

• Febrile neutropenia (FN) carries 5-20% mortality in high-risk hematological malignancies (- Tintinalli's Emergency Medicine, p. 2755)
• In Nepal, hematological malignancies are rising but data on FN epidemiology is scarce. The only major Nepali study found is Shilpakar et al. (2019) on procalcitonin/CRP in acute leukemia FN (J Glob Oncol) - referenced in a 2025 Springer systematic review on FN prediction models
• Microbial flora and resistance patterns in Nepal (multidrug-resistant gram-negatives, Klebsiella, ESBL producers) differ fundamentally from Western data
• CSH sees a significant volume of hematology patients (leukemia, lymphoma, myeloma post-chemotherapy) - making it an ideal single-center study site
• Buffy coat provides rapid bedside diagnosis of bacteremia (visible organisms), blast detection in leukemic crises, and identification of microfilariae/Leishmania - all relevant in Nepal's context

---

3. Objectives

Primary Objective

• To describe the clinical profile and microbiological spectrum of febrile neutropenia in patients with hematological malignancies at CSH

Secondary Objectives

1. To determine the frequency and type of organisms isolated from blood cultures and buffy coat
2. To assess antimicrobial sensitivity/resistance patterns of isolated organisms
3. To evaluate outcomes (treatment response, ICU admission, 30-day mortality) in FN episodes
4. To compare yield of buffy coat examination vs. conventional blood culture in early diagnosis
5. To identify risk factors associated with poor outcomes (MASCC score, neutropenia depth, malignancy type)

---

4. Data to Collect - Variable List

A. Patient Demographics

B. Underlying Hematological Malignancy

C. Neutropenia Characterization

D. Clinical Assessment at FN Episode

E. Laboratory Investigations (Core Dataset)

F. Buffy Coat Specific Data (Your Differentiating Variable)

G. Microbiology Outcomes

H. Treatment Variables

I. Outcomes (Primary Endpoints)

---

5. Study Design

---

6. Where the Buffy Coat Fits

1. Rapid diagnosis angle: Standard blood culture at CSH takes 24-72 hours. Buffy coat smear takes 2-3 hours. For septic/rapidly deteriorating FN patients this timing difference matters.
2. Resource-limited setting relevance: Galactomannan, PCR-based diagnostics are expensive/unavailable in Nepal. Buffy coat is a cheap, microscopy-based test.
3. Dual role in hematological malignancies: It detects both organisms (bacteremia/fungemia) AND blast percentage (leukemic cells) - useful when bone marrow biopsy is delayed.
4. Nepal-specific organisms: Leishmania donovani (Kala-azar is endemic in Terai), microfilariae - both detectable on buffy coat - are missed on blood culture.

---

7. Data Collection Tools

1. Proforma/Case Record Form (CRF): Design a structured 2-page paper form covering all variables above. Get it approved by your supervisor and CSH IRC (Institutional Review Committee).
2. IRC/Ethics Approval: Submit to CSH Ethical Review Committee. Since this is observational with standard-of-care tests, approval is typically expedited.
3. MASCC Score Sheet: Print and fill at admission for every episode (score ≥21 = low risk; <21 = high risk).
4. Lab coordination: Pre-arrange with CSH microbiology for:
   • Buffy coat preparation protocol (standardize the centrifugation, staining, reading steps)
   • BACTEC blood culture system access
   • AST reporting format (CLSI)

---

8. Statistical Analysis Plan

---

9. Key References to Cite

1. Shilpakar R et al. (2019) - Procalcitonin and CRP as bacteremia markers in FN in acute leukemia: a prospective study from Nepal (J Glob Oncol 5:1-6) - this is your most important local reference
2. MASCC/ESMO Guidelines on febrile neutropenia management
3. IDSA 2010 Guidelines for FN (Freifeld et al., CID 2011) - still gold standard
4. Chen Y-H et al. (2025) - Antibiotic de-escalation in FN: systematic review and meta-analysis (Antimicrob Agents Chemother, PMID: 40079575)
5. Tintinalli's Emergency Medicine (9th ed.) - for definition criteria and management protocol

---

10. Thesis Chapter Structure (DM Format)

1. Introduction - Epidemiology of hematological malignancies; definition, incidence, and mortality of FN; gap in Nepal data; role of buffy coat
2. Review of Literature - Global FN data; South Asian data; Nepali studies; buffy coat utility; MASCC scoring; antimicrobial resistance trends
3. Objectives - As listed above
4. Materials and Methods - Study design, setting, eligibility, data collection, lab protocol, statistical analysis, ethical clearance
5. Results - Demographic table, malignancy profile, FN characteristics, microbiology table, buffy coat findings, treatment and outcomes table, risk factor analysis
6. Discussion - Compare your data with Shilpakar 2019, Indian studies, global benchmarks; discuss MDR implications for Nepal; buffy coat utility in resource-limited settings
7. Conclusion and Recommendations
8. Bibliography (Vancouver style for medical theses in Nepal)
9. Annexures - CRF/proforma, MASCC score sheet, consent form, ethical approval letter

---

Immediate Next Steps

1. Concept paper/synopsis: Write a 3-page synopsis covering title, objectives, methodology, sample size, and timeline - submit to your DM department and IRC
2. Supervisor meeting: Confirm the buffy coat preparation protocol is feasible at CSH microbiology lab
3. Pilot run: Do a 10-patient pilot in the first 2-4 weeks to test your CRF and buffy coat protocol before full enrollment
4. Literature review: Read Shilpakar et al. 2019 (available through J Glob Oncol) and the IDSA 2010 FN guidelines as your two anchor references

---

COMPLETE DM THESIS PROTOCOL

Buffy Coat-Derived Granulocyte Transfusion vs. Standard Care in Febrile Neutropenia in Hematological Malignancies: A Prospective Randomized Controlled Trial

---

SECTION 1: TITLE PAGE

---

SECTION 2: BACKGROUND AND RATIONALE

The Problem

• Fever: Single oral temperature ≥38.3°C (101°F) OR ≥38.0°C (100.4°F) sustained >1 hour
• Neutropenia: ANC <500/mm³ OR ANC <1000/mm³ expected to fall below 500

The Granulocyte Gap

• Migrate to infection sites and kill organisms by oxidative burst, degranulation, and phagocytosis
• Can reduce time to ANC recovery (Ramachandran et al. 2023, PMID 38023414: 4.5 days vs. 8 days, p=0.01)
• Are most beneficial for refractory bacterial/fungal infections unresponsive to antibiotics

The Cost-Access Barrier in Nepal

Published Precedent

• 60 children randomized (GT arm vs. standard treatment arm)
• ANC recovery significantly faster in GT arm (4.5 vs. 8 days, p=0.01)
• 28-day mortality comparable; no major adverse events
• Conclusion: Safe, leads to early hematological recovery; adult data needed

Why ASH Will Be Interested

• Granulocyte biology falls under ASH Blood's category: "Phagocytes, Granulocytes and Myelopoiesis"
• The RING trial (the highest-profile GT trial globally) was underpowered - new RCT data is needed
• Resource-limited setting data is explicitly under-represented in Blood Advances
• Nepal-specific MDR organism data is novel
• Real-world cost-effectiveness angle is publishable

---

SECTION 3: OBJECTIVES

Primary Objective

Secondary Objectives

1. Time to ANC recovery (ANC ≥500/mm³ for 2 consecutive days)
2. Time to fever defervescence (afebrile ≥24 hours without antipyretics)
3. Duration of IV antibiotic therapy
4. Length of hospital stay (days)
5. ICU admission rate
6. 30-day and 90-day overall survival
7. Adverse events of granulocyte transfusion (TRALI, allergic reaction, alloimmunization, CMV transmission)
8. Microbiological clearance rates (blood culture conversion)
9. Cost comparison (buffy coat GT vs. apheresis GT; GT arm vs. ST arm total treatment cost)
10. Correlation of granulocyte dose administered (cells/kg) with ANC recovery

---

SECTION 4: STUDY DESIGN

---

SECTION 5: ELIGIBILITY CRITERIA

Inclusion Criteria

1. Age 18-65 years
2. Confirmed hematological malignancy (AML, ALL, CML blast crisis, CLL, NHL, HL, Multiple Myeloma, MDS, HSCT recipients)
3. Chemotherapy-induced high-risk febrile neutropenia (MASCC score <21)
4. ANC <500/mm³ at fever onset
5. Fever ≥38.3°C once OR ≥38.0°C for >1 hour
6. High-risk criteria present (ANY one of):
   • Expected neutropenia duration >7 days
   • Clinically documented or microbiologically confirmed infection
   • Inpatient at time of fever onset
   • Significant comorbidity
7. No response to empirical antibiotics after 48-72 hours (for GT consideration) - OR prospective enrollment at FN onset
8. Written informed consent

Exclusion Criteria

1. Age <18 years or >65 years
2. Non-hematological malignancy
3. Low-risk FN (MASCC score ≥21 with expected short neutropenia)
4. Active CMV disease or known CMV-negative status with CMV-negative irradiated blood unavailable
5. Alloimmunized to HLA antigens (if detectable)
6. Drug fever, transfusion reaction fever as cause
7. DNACPR or palliative intent only
8. Pregnancy
9. Prior granulocyte transfusion in the same admission
10. Known refusal of blood products

---

SECTION 6: INTERVENTION PROTOCOL

Arm A - Granulocyte Transfusion (GT) Arm

1. Collect 4-6 units of whole blood (ABO/Rh compatible with patient)
2. Centrifuge at 3,000 rpm for 10 minutes (hard spin)
3. Extract buffy coat layer (contains granulocytes + platelets + RBCs) ~50ml per unit
4. Pool buffy coat from 4-6 units into single transfer bag
5. Irradiate at 25 Gy (mandatory - prevents TA-GvHD)
6. Check final granulocyte count (target ≥1×10¹⁰ cells per transfusion)
7. Transfuse within 6 hours of preparation (granulocytes lose viability rapidly)

• Paracetamol 500-1000 mg IV/oral
• Hydrocortisone 100 mg IV
• Chlorpheniramine 4 mg IV

• 10 mL/kg of pooled buffy coat every alternate day
• Continue until: afebrile ≥24h without antipyretics + ANC ≥500 for 2 consecutive days
• OR occurrence of life-threatening adverse event
• OR maximum 5 transfusions

• ABO/Rh cross-match before each unit
• CMV-negative donors preferred (or leukoreduced/irradiated)
• Granulocyte count of final product recorded before issue

Arm B - Standard Treatment (ST) Arm

• Empirical IV antibiotics within 60 min of fever
• Beta-lactam monotherapy (Piperacillin-tazobactam OR Cefepime OR Meropenem) based on MASCC score and local antibiogram
• Antifungal escalation (Fluconazole → Voriconazole/Caspofungin) if fever >96 hours unresponsive
• G-CSF (Filgrastim) per institutional protocol
• Transfusion support (pRBC, platelets) per standard thresholds

---

SECTION 7: COMPLETE DATA COLLECTION FORM (CRF)

---

MODULE A: PATIENT IDENTIFICATION AND DEMOGRAPHICS

Study ID: _______  Date of Enrollment: ___/___/____
Arm (GT/ST): _______  Randomization envelope no.: _______

1.  Full name (initials only for data): _______
2.  Age (years): _______
3.  Sex: M / F / Other
4.  Address (district/zone): _______ (urban / peri-urban / rural)
5.  Ethnicity/caste: Brahmin/Chhetri / Janajati / Madhesi / Dalit / Other
6.  Occupation: _______
7.  Monthly household income (NPR): <10,000 / 10,000-30,000 / >30,000
8.  Health insurance: Yes / No (type: _______)
9.  Referral from: OPD / IPD (same hospital) / External referral (hospital name: _______)
10. Height (cm): _______ Weight (kg): _______ BMI: _______
11. ECOG Performance Status at admission: 0 / 1 / 2 / 3 / 4
12. Smoking: Yes / No / Ex-smoker  Alcohol: Yes / No
13. Comorbidities: DM / HTN / CKD / CLD / IHD / HIV / TB / None / Other: _______

---

MODULE B: UNDERLYING HEMATOLOGICAL MALIGNANCY

14. Primary diagnosis: 
    [ ] AML  [ ] ALL  [ ] CML (blast crisis)  [ ] CLL
    [ ] Diffuse Large B-cell Lymphoma (DLBCL)
    [ ] Hodgkin Lymphoma (HL)
    [ ] Multiple Myeloma (MM)
    [ ] MDS   [ ] MDS/AML   [ ] HSCT recipient
    [ ] Other: _______

15. WHO/ICC 2022 subtype (if AML/ALL): _______
16. Cytogenetics/molecular markers:
    - FISH/PCR results: _______
    - Key markers: FLT3-ITD / NPM1 / BCR-ABL1 / RUNX1::RUNX1T1 / PML::RARA / Other: _______
    - Risk stratification (ELN 2022 for AML): Favorable / Intermediate / Adverse

17. Date of initial diagnosis: ___/___/____
18. Disease status at time of FN episode:
    [ ] Newly diagnosed, on induction
    [ ] Complete remission (CR1/CR2/CR3: ___)
    [ ] Partial remission
    [ ] Relapsed   [ ] Refractory
    [ ] Post-HSCT (Day post-transplant: ___)

19. Chemotherapy regimen received:
    Regimen name: _______ (e.g., 7+3, HyperCVAD, DHAP, BEP)
    Cycle number: _______
    Last day of chemotherapy: ___/___/____
    Days from last chemo to fever onset: _______
    
20. G-CSF prophylaxis given (before this FN episode): Yes / No
    If yes: Agent: Filgrastim / Pegfilgrastim  Dose/day: _______
    
21. Prior lines of therapy: 1 / 2 / 3 / >3
22. Prior HSCT: Yes / No  (autologous / allogeneic; donor type: _______)
23. Bone marrow biopsy result (most recent):
    Cellularity: _______%   Blasts: _______%   Date: ___/___/____

---

MODULE C: FEBRILE NEUTROPENIA EPISODE CHARACTERIZATION

24. Date and time of fever onset: ___/___/____ ____:____
25. Fever pattern: Continuous / Intermittent / Hectic
26. Maximum recorded temperature (°C): _______
27. ANC at fever onset (/mm³): _______
    Neutropenia grade: Mild (500-1000) / Severe (<500) / Profound (<100)
28. Hemoglobin at fever onset (g/dL): _______
29. Platelet count at fever onset (/mm³): _______

30. MASCC RISK SCORE (calculate at admission):
    Burden of illness (mild/no symptoms = 5; moderate = 3): ___
    No hypotension: +5
    No COPD: +4
    Solid tumor OR no prior fungal infection: +4
    No dehydration: +3
    Outpatient status: +3
    Age <60 years: +2
    TOTAL MASCC SCORE: _______  (≥21 = low risk; <21 = HIGH RISK)

31. CISNE score (if applicable for outpatient consideration):
    ECOG ≥2: +2; Stress-induced hyperglycemia: +2; COPD: +1; CVC: +1; 
    Mucositis grade ≥2: +1; Monocytes <200: +1
    TOTAL CISNE: _______

32. Clinical site of infection (if identified):
    [ ] No focus identified (primary bacteremia)
    [ ] Pneumonia (radiological/clinical)
    [ ] Urinary tract infection
    [ ] Skin/soft tissue (cellulitis, wound)
    [ ] Central line/catheter-related infection (CLABSI)
    [ ] Oropharyngeal mucositis ± infection
    [ ] Perianal infection/typhlitis (neutropenic enterocolitis)
    [ ] Intra-abdominal
    [ ] CNS (meningitis/encephalitis)
    [ ] Sinusitis (fungal sinusitis?)
    [ ] Bacteremia/sepsis (no clear focus)
    [ ] Multiple sites
    [ ] Other: _______

33. Mucositis: Yes / No
    WHO Mucositis Grade: 0 / 1 / 2 / 3 / 4
    
34. Central venous catheter in situ: Yes / No
    If yes: Type: PICC / Hickman / Port-a-cath / Temporary CVL
    Duration of catheter (days): _______
    Signs of catheter infection: Yes / No
    
35. Sepsis criteria (Sepsis-3):
    Suspected infection: Yes
    SOFA score: _______ (increase ≥2 = sepsis)
    Septic shock: Yes / No (vasopressor required + lactate >2 mmol/L)
    
36. Shock at presentation: Yes / No
    If yes: Type: Septic / Distributive  Vasopressor needed: Yes / No

---

MODULE D: LABORATORY DATA - COMPLETE PANEL

=== HEMATOLOGY ===
37. CBC with 5-part differential (Daily for first 14 days, then every 48h):
    - WBC (/mm³): _______
    - ANC (/mm³): _______  [= WBC × (Neutrophil% + Band%)]
    - Hemoglobin (g/dL): _______
    - Platelets (/mm³): _______
    - Reticulocytes (%): _______
    - Peripheral blood blast %: _______
    - Metamyelocytes/bands seen: Yes / No (count: ___)

=== BIOCHEMISTRY ===
38. Serum creatinine (mg/dL): _______  eGFR: _______
39. Blood urea nitrogen (mg/dL): _______
40. Serum sodium (mEq/L): _______  Potassium: _______  Chloride: _______
41. Total bilirubin (mg/dL): _______  Direct: _______
42. AST (U/L): _______  ALT: _______  ALP: _______  GGT: _______
43. Total protein (g/dL): _______  Albumin: _______
44. Serum LDH (U/L): _______
45. Serum uric acid (mg/dL): _______
46. Blood glucose (mg/dL): _______  (random / fasting)
47. PT (sec): _______  INR: _______  aPTT: _______
48. Fibrinogen (mg/dL): _______
49. D-dimer (mg/L): _______
50. Serum ferritin (ng/mL): _______   (screen for HLH)
51. Triglycerides (mg/dL): _______    (screen for HLH)
52. Serum lactate (mmol/L): _______

=== INFLAMMATORY MARKERS ===
53. C-Reactive Protein (mg/L): _______  (Day 0, 3, 7, at defervescence)
54. Erythrocyte Sedimentation Rate (mm/hr): _______
55. Procalcitonin (ng/mL): _______   (key: <0.5 = unlikely bacteremia)
56. Interleukin-6 (pg/mL): _______ (if available - for ASH publication bonus data)

=== MICROBIOLOGY ===
57. Blood culture x2 (peripheral vein, 10 mL each into aerobic + anaerobic bottles):
    - Collection time: ____:____
    - Bottle 1: Organism: _______  Sensitivity: _______  Result day: ___
    - Bottle 2: Organism: _______  Sensitivity: _______  Result day: ___
    
58. If CVC present - Blood culture from CVC port:
    - Collection time: ____:____
    - Organism: _______  Sensitivity: _______
    - Differential time to positivity (DTP): _______min (CVC vs. peripheral)
    (DTP ≥120min = CLABSI)

59. Urine culture (midstream/catheter):
    - Organism: _______  Colony count: _______  Sensitivity: _______

60. Sputum/BAL culture (if cough/pulmonary infiltrates):
    - Organism: _______  Sensitivity: _______

61. Wound/skin swab culture (if applicable): _______

62. CSF culture (if neurological signs): Organism: _______  Cell count: _______

63. Stool culture (if diarrhea): Organism: _______

64. Throat swab culture: _______

65. Fungal markers:
    - Serum Galactomannan (Aspergillus Ag) index: _______ (>0.5 = positive)
    - Beta-D-Glucan (pg/mL): _______ (>80 = positive, >200 = strongly positive)
    - KOH mount (any specimen): Positive / Negative / Not done
    - Fungal blood culture: Organism: _______

66. Viral screening:
    - CMV PCR (copies/mL): _______  (pre- and post-transfusion)
    - EBV PCR: _______
    - HSV serology: IgM / IgG
    - HIV Ag/Ab: Positive / Negative
    - HBsAg: _______ Anti-HCV: _______

67. ORGANISM CHARACTERIZATION TABLE (fill per isolate):
    | # | Specimen | Organism | Gram +/- | Antibiogram | ESBL | CRE | MRSA | MDR |
    |---|---|---|---|---|---|---|---|---|
    | 1 | | | | | | | | |
    | 2 | | | | | | | | |

=== IMAGING ===
68. Chest X-Ray (PA/AP): Date: ___  Findings: _______
69. CT Thorax (HRCT/contrast): Date: ___  Findings: _______
    Specific findings: Tree-in-bud / Ground glass / Consolidation / Nodules / 
    Halo sign (Aspergillus?) / Air crescent sign / Pleural effusion / Normal
70. CT Abdomen/Pelvis (if suspected enterocolitis/abdominal source):
    Date: ___  Findings: _______
71. CT Sinuses (if fungal sinusitis suspected): Date: ___  Findings: _______
72. Echocardiogram (if endocarditis suspected): Date: ___  Findings: _______

=== BUFFY COAT-SPECIFIC DATA ===
(To be recorded for ALL patients in GT arm; also record buffy coat smear diagnostic data for ST arm if done)

73. Buffy coat preparation details (GT arm, per transfusion episode):
    - Transfusion number (1st/2nd/3rd/4th/5th): _______
    - Date/time prepared: ___/___/____ ____:____
    - Number of whole blood units pooled: _______
    - ABO/Rh groups of donors: _______
    - Final granulocyte count of product (×10¹⁰): _______
    - Irradiation dose (Gy): _______  (confirm 25 Gy)
    - Time from preparation to transfusion (hours): _______  (must be <6h)
    - Volume transfused (mL): _______  Dose (mL/kg): _______

74. Pre-transfusion check:
    - Patient ABO/Rh: _______
    - Cross-match compatible: Yes / No
    - CMV status of product: Negative / Positive / Unknown
    - Pre-medication given: Paracetamol / Hydrocortisone / Chlorpheniramine (tick all)

75. Buffy coat smear (DIAGNOSTIC use - ALL patients):
    - Preparation: Leishman / Giemsa stain
    - Time from blood draw to smear result (hours): _______
    - WBC differential on smear: N: ___ L: ___ M: ___ E: ___ B: ___
    - Blast % on buffy coat smear: _______
    - Organisms visualized: Yes / No
      If yes: Gram-positive cocci / Gram-negative rods / Yeast forms / 
              Leishmania amastigotes / Microfilariae / Other: _______
    - Concordance with peripheral blood automated analyzer: Yes / No
    - Time advantage vs. blood culture result (hours): _______
    (This is your KEY diagnostic comparison data for the publication)

---

MODULE E: TREATMENT DATA

=== ANTIBIOTICS ===
76. Time from fever onset to first antibiotic dose (minutes): _______ (target <60 min)
77. Empirical antibiotic regimen (Day 0):
    Agent 1: _______  Dose: _______  Route: IV
    Agent 2 (if combination): _______  Dose: _______
    
78. Antibiotic modifications:
    Day modified: ___  Reason: Culture result / Non-response / Adverse effect / De-escalation
    New regimen: _______

79. Antifungal therapy:
    Started: Yes / No   Day started: ___
    Agent: Fluconazole / Voriconazole / Caspofungin / Amphotericin B
    Indication: Empirical (>96h no response) / Targeted (confirmed fungal)
    Duration: _____ days

80. Antibiotic de-escalation performed: Yes / No
    Day de-escalated: ___  Based on: Culture sensitivity / Clinical response
    
81. Total duration of IV antibiotics (days): _______
82. Antifungal prophylaxis received prior to this episode: Yes / No
    Agent: Fluconazole / Posaconazole / Other: _______

=== GRANULOCYTE TRANSFUSION (GT ARM ONLY) ===
83. Total number of GT administered: _______
84. Day of first GT (from FN onset): _______
85. Days between GTs: _______
86. Reason for stopping GT (tick one):
    [ ] ANC ≥500 achieved   [ ] Afebrile ≥24h
    [ ] Adverse event   [ ] Completed 5 cycles   [ ] Patient refusal   [ ] Death

87. GT ADVERSE EVENT LOG (per transfusion):
    | GT# | Fever | Chills/Rigor | Urticaria | Dyspnea | SpO2 drop | TRALI | Transfusion stopped |
    |---|---|---|---|---|---|---|---|
    | 1 | | | | | | | |
    | 2 | | | | | | | |
    | 3 | | | | | | | |
    | 4 | | | | | | | |
    | 5 | | | | | | | |

88. Post-transfusion CMV PCR (Day 7, Day 14): _______
89. Post-transfusion HLA alloimmunization screening (Day 30): Positive / Negative

=== SUPPORTIVE CARE ===
90. G-CSF administered during this episode: Yes / No
    Agent: Filgrastim / Pegfilgrastim  Dose: _______  Start day: ___  Total doses: ___
91. PRBC transfusion: Yes / No  Units given: ___  Hb threshold: _______
92. Platelet transfusion: Yes / No  Units given: ___  Platelet threshold: _______
93. Nutritional support: IV TPN / Enteral / Oral   Calorie goal met: Yes / No
94. Foley catheter inserted: Yes / No
95. ICU admission: Yes / No   Date: ___/___/____  Duration (days): _______
96. Vasopressor used: Yes / No  Agent: Noradrenaline / Adrenaline / Both
    Duration of vasopressors (hours): _______
97. Mechanical ventilation: Yes / No  Duration (hours): _______
98. Renal replacement therapy: Yes / No  Duration (days): _______

---

MODULE F: OUTCOMES

=== PRIMARY OUTCOME ===
99. 28-day all-cause mortality: ALIVE / DEAD
    If dead: Date of death: ___/___/____   Cause of death: _______
    (Septic shock / Respiratory failure / MDR infection / Disease progression / 
    GT adverse event / Other: _______)

=== SECONDARY OUTCOMES ===
100. Time to ANC ≥500/mm³ (days from FN onset): _______
     Date of ANC recovery: ___/___/____   ANC value: _______
     Confirmed on 2 consecutive days: Yes / No

101. Time to defervescence (days from FN onset): _______
     Date of last fever: ___/___/____
     Definition used: Afebrile >24 hours without antipyretics

102. Blood culture conversion to negative:
     Date of first negative culture: ___/___/____
     Days to culture clearance: _______

103. Duration of IV antibiotic therapy (days): _______
104. Total length of hospital stay (days): _______
105. ICU admission during this episode: Yes / No   ICU days: _______
106. 30-day overall survival: ALIVE / DEAD
107. 90-day overall survival: ALIVE / DEAD
     If dead: Date: ___  Cause: _______

=== CLINICAL RESPONSE CLASSIFICATION ===
108. Clinical response at Day 7:
     Complete response (CR): Afebrile + ANC recovering + no active infection
     Partial response (PR): Afebrile but ANC not recovered / Infection controlled
     No response (NR): Still febrile or infection progressing
     Progressive disease (PD): Worsening infection / new focus

=== COST DATA ===
109. GT cost per episode (NPR):
     - Whole blood units purchased: ___ × NPR ___/unit = NPR _______
     - Irradiation cost: NPR _______
     - Blood bank processing cost: NPR _______
     - Pre-medications: NPR _______
     - TOTAL GT COST (NPR): _______
     
110. Total antibiotic cost (NPR): _______
111. Total hospitalization cost (NPR): _______
112. Total episode cost (NPR): _______ vs. ST arm patient: _______
113. Estimated cost if apheresis GT was used (for comparison): NPR _______
     (Based on institutional quote or published pricing)

---

MODULE G: FOLLOW-UP (Day 30, Day 60, Day 90)

114. Patient status at Day 30: Alive / Dead / Lost to follow-up
115. Patient status at Day 60: Alive / Dead / Lost to follow-up
116. Patient status at Day 90: Alive / Dead / Lost to follow-up
117. Underlying malignancy status at Day 90: CR / PR / Stable / Progression / Relapse
118. Any subsequent FN episode requiring re-hospitalization: Yes / No
     If yes: Same organism / Different organism
119. ANC at Day 30 follow-up (/mm³): _______
120. Post-GT alloimmunization (HLA antibody) at Day 30: Positive / Negative

---

SECTION 8: SAMPLE SIZE CALCULATION

• 28-day mortality in GT arm: ~73% survival (27% mortality)
• 28-day mortality in ST arm: ~90% survival (10% mortality) - based on low-risk standard therapy

• Expected ANC recovery by Day 7: GT arm 70%, ST arm 40%
• α = 0.05 (two-tailed), Power = 80%
• Using proportion formula: n = [Z₀.₀₂₅ + Z₀.₂]² × [p1(1-p1) + p2(1-p2)] / (p1-p2)²
• n = ~52 per arm → 104 total + 10% dropout = ~116 patients

---

SECTION 9: STATISTICAL ANALYSIS PLAN

---

SECTION 10: ETHICAL CONSIDERATIONS

1. IRC submission: Civil Service Hospital Institutional Review Committee
2. Informed consent: Written, bilingual (English + Nepali); separate consent for GT
3. CTRI registration: Before first patient enrollment (mandatory for ASH)
4. DSMB: At least 1 independent hematologist + 1 statistician outside CSH
5. GCP compliance: Good Clinical Practice training for all team members
6. Adverse event reporting: Grade 3-4 adverse events within 24 hours to IRC

---

SECTION 11: THESIS CHAPTER STRUCTURE

1. Introduction (1,500 words): FN burden; granulocyte biology; apheresis limitations; buffy coat rationale; cost context in Nepal; study gap
2. Review of Literature (3,000 words): GT history; RING trial; Cochrane review; Ramachandran 2023; South Asian data; MASCC/IDSA guidelines; Nepal FN data (Shilpakar 2019)
3. Objectives (one page)
4. Methodology (2,500 words): Full protocol as above; CRF attached as appendix
5. Results (2,500 words + tables/figures): CONSORT flow; Table 1 (baseline); Table 2 (outcomes); Figure 1 (Kaplan-Meier ANC recovery); Figure 2 (Kaplan-Meier survival); Table 3 (microbiology); Table 4 (cost comparison)
6. Discussion (2,500 words): Compare with Ramachandran 2023; RING trial; cost implications; MDR data unique to Nepal; limitations
7. Conclusion (300 words)
8. References (Vancouver; max 80 for Blood Advances)
9. Appendices: CRF, MASCC calculator, consent forms (Nepali + English), ethical approval

---

SECTION 12: TARGET JOURNAL STRATEGY FOR ASH

Primary Target: Blood Advances (ASH) - IF 7.7

• Category: "Clinical Trials and Observations" OR "Phagocytes, Granulocytes and Myelopoiesis"
• Word limit: ~4,500 words main text; abstract 250 words
• Open access; strong preference for resource-limited setting and novel interventional data
• Submit via: bloodadvances.org

Alternative Targets (if rejected):

1. Blood Neoplasia (ASH journal, hematological malignancies focus)
2. Annals of Hematology (Springer; IF ~3.5)
3. Leukemia and Lymphoma (Taylor & Francis; IF ~3.0)
4. Journal of Global Oncology (ASCO; previously published Shilpakar Nepal data)

Cover Letter Key Points:

• Only RCT from Nepal (and one of very few from South Asia) on GT in adult hematological malignancies
• Addresses the exact gap identified by Ramachandran 2023 (adult data needed)
• Provides cost-effectiveness data for the 70% of the world that cannot afford apheresis GT
• Falls under ASH Blood's explicit priority: "clinical investigations advancing hematologic practice globally"

---

SECTION 13: KEY REFERENCES (Vancouver format)

1. Ramachandran M, Gupta AK, Meena JP, et al. A randomized controlled trial to explore the safety and efficacy of irradiated buffy-coat granulocytes in pediatric patients with febrile neutropenia. Am J Blood Res. 2023;13(5):152-61. PMID: 38023414
2. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-93.
3. Shilpakar R, Paudel BD, Neupane P, et al. Procalcitonin and C-Reactive Protein as markers of bacteremia in patients with febrile neutropenia who receive chemotherapy for acute leukemia: a prospective study from Nepal. J Glob Oncol. 2019;5:1-6.
4. Price TH, Boeckh M, Harrison RW, et al. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood. 2015;126(18):2153-61. [RING Trial]
5. Estcourt LJ, Stanworth S, Doree C, et al. Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2016;4:CD005341.
6. Phetsai W, Sanpakit K, Buaboonnam J, et al. Granulocyte transfusion improves survival in pediatric febrile neutropenia: a 15-year cohort study. Clin Exp Pediatr. 2026. PMID: 41531154
7. Chen Y-H, Sun AY-E, Narain K. Efficacy and safety of early antibiotic de-escalation in febrile neutropenia for patients with hematologic malignancy: a systematic review and meta-analysis. Antimicrob Agents Chemother. 2025. PMID: 40079575
8. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111-v118.

---

CHECKLIST: NOTHING MISSED

• CTRI registration number in the manuscript
• CONSORT 2010 flow diagram included
• IRB/IRC approval letter attached
• All patients have signed consent documented
• DSMB minutes documented
• Data sharing statement included
• Author contributions (CRediT taxonomy) filled
• Conflict of interest declarations signed
• Funding statement (even if "no funding" - state it)
• Supplementary data files (individual patient data, statistical code) prepared
• Abstract structured: Background / Methods / Results / Conclusions (≤250 words)
• Word count checked (<4,500 for Regular Article or <2,500 for Brief Report)
• All figures at ≥300 DPI
• Kaplan-Meier plots for ANC recovery and survival generated
• Cost table in NPR with USD equivalent ($1 ≈ NPR 132)

---

---

What's Inside (13 Sheets)

Key Features

• Colour coding: Red = mandatory, Grey = auto-calculated (don't touch), Green = GT arm only, Yellow = cost fields
• Dropdowns everywhere: Arm, diagnosis, MASCC components, organism, antibiogram, outcomes - no free-text errors
• MASCC score auto-totals as you select each component
• Buffy coat concordance auto-classifies True Positive/Negative/False Positive/Negative instantly
• Time saved vs culture auto-calculates in hours - this is your key ASH publication number
• Dashboard counts GT vs ST arm mortality, ANC recovery days, costs - ready to copy into your results table